



Pharmaceuticals Limited

Registered & Corporate Office :

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,
Opp. SBI Executive Enclave, Banjara Hills,
Hyderabad - 500 034, Telangana, INDIA.
Tel : +91-40-2525 9999, Fax : +91-40-2525 9889
CIN : L24239TG1987PLC008066
Email: info@smspharma.com, www.smspharma.com

Date: 26th November, 2025

To
The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Security Code: 532815

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E), Mumbai
- 400 051.
Symbol: SMSPHARMA

Dear Sir/Madam,

Sub: Press Release

Please find enclosed the press release titled "SMS Pharmaceutical's Associate Company, VKT Pharma, receives US FDA approval for its reformulated Ranitidine"

The above information will also be made available on the website of the Company at www.smspharma.com

This is for your information and records.
Thanking you

Yours Faithfully
For SMS Pharmaceuticals Limited

Thirumalesh Tumma
Company Secretary

Encl: Press Release



November 26, 2025

SMS Pharmaceutical's associate company, VKT Pharma, receives US FDA approval for its reformulated Ranitidine

SMS Pharmaceuticals Limited (SMS Pharma) (NSE: SMSPHARMA; BSE: 532815) is pleased to announce that the US Food and Drug Administration has approved its associate company VKT Pharma's reformulated Ranitidine tablets in 150mg and 300mg strengths. This approval marks the re-entry of this important acid-reducing medication into the US market after a five-year absence.

The approval by the US FDA comes after extensive safety testing and manufacturing improvements that address previous concerns regarding the formation of NDMA impurity. It is expected to increase patient access to this important medication for patients who rely on it for various health conditions.

For any further information, please contact:

Company	Investor relations
SMS Pharmaceuticals Limited	Eqsponent
Mr. Thirumalesh Tumma Email: complianceofficer@smspharma.com	Mr. Aditya Dutta Email: smspharma.IR@eqsponent.com

DISCLAIMER

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. SMS Pharmaceuticals Limited will not be in any way responsible for any action taken based on such statements and discussions; undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.